← All stocks

Cogent Biosciences, Inc.

COGT Net selling

CIK 0001622229 #1211 in the set updated 17 Sep 2026

Bought (12 mo)

$0.00

out of their own pocket, the only kind of buying there is

Sold (12 mo)

$383.89M

$0.00 on a plan · $244.31M straight out of an exercise

Sold at will

$139.58M

5 of 8 sales

Net

−$383.89M

−$139.58M against sales at will

By person

8 insiders · 8 transactions

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Fairmount Funds Management LLC entity

Director

—

$370.02M (2) scheduled

−$370.02M

5,503,418

3.17%

$206.60M

−11.6%

Robinson John Edward

Chief Scientific Officer

—

$3.49M (1)

−$3.49M

140,002

0.0807%

$5.26M

—

Sachs Jessica

Chief Medical Officer

—

$3.20M (1)

−$3.20M

133,938

0.0772%

$5.03M

+10,235%

Green John L.

Chief Financial Officer

—

$2.98M (1)

−$2.98M

131,834

0.0760%

$4.95M

+3,332%

Kearns Evan

Chief Legal Officer

—

$2.52M (1)

−$2.52M

109,398

0.0630%

$4.11M

—

Morris Arlene

Director

—

$1.69M (2) scheduled

−$1.69M

0.0000%

$0.00

—

Robbins Andrew R

President and CEO

—

657,503

0.3789%

$24.68M

—

Pinnow Cole

Chief Commercial Officer

—

216,650

0.1249%

$8.13M

+5,755%

Individual transactions

Insider

Date

Role

Action

Price

Amount

Morris Arlene

27 Aug 2026

Director

Sold after exercise

3,161

$37.54

$118.66K

Morris Arlene

27 Aug 2026

Director

Sold after exercise

42,349

$37.09

$1.57M

Fairmount Funds Management LLC

31 Mar 2026

Director

Sold after exercise indirect

7,000,000

$34.66

$242.62M

Show all 8 transactions →

What was left out

Form 4 filings counted 24

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 0

Sales on a Rule 10b5-1 plan 0

Sales straight out of an exercise 3

Sales at will 5

Transactions with no price 0

Shares from compensation/vesting 11,072,130

History held since 3 Apr 2018